Capital Performance Advisors LLP Avidity Biosciences, Inc. Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 21 shares of RNA stock, worth $879. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21Holding current value
$879% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
216Shares Held
95.8MCall Options Held
171KPut Options Held
196K-
Price T Rowe Associates Inc Baltimore, MD10.9MShares$457 Million0.05% of portfolio
-
Rtw Investments, LP New York, NY8.81MShares$369 Million6.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$361 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.51MShares$272 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$249 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.18B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...